Drug Type Small molecule drug |
Synonyms Larotaxel, PNU 100940, PNU-100940 + [8] |
Target |
Action inhibitors |
Mechanism Tubulin inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC45H57NO16 |
InChIKeySEFGUGYLLVNFIJ-QDRLFVHASA-N |
CAS Registry192573-38-9 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | Larotaxel Dihydrate | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Locally Advanced Bladder Carcinoma | Phase 3 | United States | 01 Feb 2008 | |
| Locally Advanced Bladder Carcinoma | Phase 3 | Argentina | 01 Feb 2008 | |
| Locally Advanced Bladder Carcinoma | Phase 3 | Australia | 01 Feb 2008 | |
| Locally Advanced Bladder Carcinoma | Phase 3 | Belgium | 01 Feb 2008 | |
| Locally Advanced Bladder Carcinoma | Phase 3 | Brazil | 01 Feb 2008 | |
| Locally Advanced Bladder Carcinoma | Phase 3 | Canada | 01 Feb 2008 | |
| Locally Advanced Bladder Carcinoma | Phase 3 | Chile | 01 Feb 2008 | |
| Locally Advanced Bladder Carcinoma | Phase 3 | France | 01 Feb 2008 | |
| Locally Advanced Bladder Carcinoma | Phase 3 | India | 01 Feb 2008 | |
| Locally Advanced Bladder Carcinoma | Phase 3 | Israel | 01 Feb 2008 |





